Persona:
Rodríguez Del Cerro, María Cruz

Foto de perfil
Dirección de correo electrónico
ORCID
0000-0001-9449-212X
Fecha de nacimiento
Proyectos de investigación
Unidades organizativas
Puesto de trabajo
Apellidos
Rodríguez Del Cerro
Nombre de pila
María Cruz
Nombre

Filtros

20252
Restablecer filtros

Ajustes

Autor: Guillamón Fernández, Antonio × search.filters.applied.f.itemFacultad: Facultad de Psicología ×

Resultados de la búsqueda

Mostrando 1 - 2 de 2
  • No hay miniatura disponible
    Publicación
    The GnRH Agonist Triptorelin Causes Reversible, Focal, and Partial Testicular Atrophy in Rats, Maintaining Sperm Production
    (MDPI, 2025-07-08) Marcos, Alberto; Rodríguez Del Cerro, María Cruz; Fernández, Rosa María; Pásaro, Eduardo; Arias-Ramos, Nuria; López-Larrubia, Pilar; González-Peramato, Pilar; Guillamón Fernández, Antonio; De Miguel, Maria P.
    We aim to provide a translational model to investigate the reproductive consequences of pubertal delay using the GnRH agonist triptorelin in transgender girls, tested in particular on testicular maturation in peripubertal rats. A total of 30 Sprague Dawley rats were utilized, with 10 subjects assigned to each of three groups from day P30 postpartum (prepubertal) until day P95 (postpubertal), mimicking treatment timing in patients. Rats received triptorelin at three time points (P30, P50, and P71), or only at P30 and P50. Control rats were injected with vehicle. Plasma testosterone levels were determined using MRM analysis. Testes and epididymides were examined histologically. There were significantly lower testosterone levels at postnatal day 48 in treated rats, indicating delayed puberty, with further reductions by day 69. By day 93, testosterone levels had recovered in rats given vehicle at P71 but remained low in the triptorelin-continuous group, suggesting the reversibility of the treatment. Treated rats had smaller testes; however, the majority of the testicular parenchyma was unaffected, with most seminiferous tubules displaying complete spermatogenesis. However, focal atrophic changes were observed in 1–30% of the parenchyma. One-third of the short-term group and half of the long-term group were classified as atrophic. Despite these changes, all treated rats had mature sperm in the epididymis, ensuring their fertility. In conclusion, triptorelin treatment promotes a decline in testosterone levels accompanied by discrete atrophy of the seminiferous tubules, which is partially reversible and compatible with sperm production and fertility preservation. Triptorelin could be an appropriate treatment prior to estrogen therapy for patients seeking gender transition.
  • Miniatura
    Publicación
    The effects of feminization hormone therapy on the brain of transgender women: A hypothesis
    (2025-12-30) Zubiaurre-Elorza, Leire; Uribe, Carme; Marcos, Alberto; Fernández, Rosa; Pásaro, Eduardo; Rodríguez Del Cerro, María Cruz; Burke, Sarah M.; Guillamón Fernández, Antonio; European Commission; Agencia estatal de Investigación (España)
    Gender-affirming hormone therapy (GAHT) is a medical treatment used to help trans- gender individuals align their physical appearance with their gender identity. GAHT in transgender women (TW) has been found to lead to a reduction in brain tissue with an expansion of the ventricles. We discuss an animal model studying the effects of GAHT that suggests dehydration of brain tissue and an alteration in the relative con- centration of brain metabolites. We hypothesize that estradiol, acting on astrocytes, alters cerebral blood flow, water metabolism, and metabolite concentration and argue that these changes could explain the higher risk of stroke observed n GAHT-treated TW compared to untreated cisgender men. Future studies should clarify the mecha- nisms underlying the brain tissue changes induced by GAHT.